Core Insights - The article provides an overview of the latest fund net asset values, highlighting the top-performing and bottom-performing funds in the market [1] Fund Performance Summary Top 10 Funds by Net Value Growth - The top 10 funds with the highest net value growth include: 1. E Fund S&P Biotechnology RMB C: 1.5967, growth of 3.31% 2. E Fund S&P Biotechnology RMB A: 1.6184, growth of 3.31% 3. E Fund S&P Biotechnology USD A: 0.2284, growth of 3.30% 4. E Fund S&P Biotechnology USD C: 0.2253, growth of 3.30% 5. Vanguard Growth A: 1.0911, growth of 2.95% 6. Shenwan Hongyuan Medical A: 0.4952, growth of 2.95% 7. Vanguard Growth C: 1.1104, growth of 2.95% 8. Shenwan Hongyuan Medical C: 0.4867, growth of 2.94% 9. Fuguo Medical Innovation A: 1.8086, growth of 2.86% 10. Fuguo Medical Innovation C: 1.7890, growth of 2.86% [2] Bottom 10 Funds by Net Value Decline - The bottom 10 funds with the largest net value decline include: 1. Dongcai Value Start C: 0.8164, decline of 5.32% 2. Dongcai Value Start A: 0.8302, decline of 5.31% 3. HSBC Jintrust Low Carbon Pioneer A: 3.0533, decline of 4.87% 4. HSBC Jintrust Low Carbon Pioneer C: 2.9915, decline of 4.87% 5. HSBC Jintrust Research Selected Mixed: 1.0754, decline of 4.86% 6. HSBC Jintrust Core Growth A: 1.0195, decline of 4.70% 7. HSBC Jintrust Core Growth C: 0.9970, decline of 4.69% 8. Ping An Research Selected Mixed C: 0.8939, decline of 4.65% 9. Ping An Research Selected Mixed A: 0.9228, decline of 4.64% 10. HSBC Jintrust Intelligent Manufacturing Pioneer C: 2.8535, decline of 4.63% [3] Market Overview - The Shanghai Composite Index opened lower but rebounded, closing slightly down, with a trading volume of 1.96 trillion yuan and a stock performance ratio of 1758 gainers to 3563 losers [5] - Leading sectors include insurance, oil, banking, textiles, and household appliances, while the concept of immunotherapy saw a rise of over 2% [6] - Declining sectors include mineral products and electrical equipment, both dropping over 2% [7] Fund Holdings Analysis E Fund S&P Biotechnology Holdings - The fund's top holdings include: 1. CRISPR Therapeutics AG: 2.14% 2. Exelixis Inc: 1.89% 3. AbbVie Inc: 1.89% 4. Madrigal Pharmaceuticals Inc: 1.84% 5. Moderna Inc: 1.83% - The fund has a concentration of 18.47% in its top ten holdings, focusing on the pharmaceutical sector, and has outperformed the market [8] Dongcai Value Start Holdings - The fund's top holdings include: 1. Longi Green Energy: -7.35% 2. Foster: -6.08% 3. Zhongyou Technology: -2.11% 4. Yinke Co.: -0.74% 5. Xinyi Solar: -4.27% - The fund has a concentration of 47.27% in its top ten holdings, focusing on the renewable energy sector, and has underperformed the market [8]

Group 1 - The core point of the news is that Chuanheng Co., Ltd. experienced a decline of 5.05% in its stock price, reaching 36.87 CNY per share, with a trading volume of 247 million CNY and a turnover rate of 1.11%, resulting in a total market capitalization of 22.405 billion CNY [1] - Chuanheng Co., Ltd. is based in Guizhou Province and was established on November 25, 2002. It was listed on August 25, 2017. The company's main business involves the production and sales of phosphoric acid and phosphate products [1] - The revenue composition of Chuanheng Co., Ltd. includes phosphoric acid (28.41%), feed-grade dicalcium phosphate (25.11%), monoammonium phosphate (21.29%), iron phosphate (9.46%), phosphate rock (6.93%), other products (3.56%), trading income (1.94%), others (1.57%), iron concentrate (1.11%), and ammonium sulfate (0.61%) [1] Group 2 - From the perspective of fund holdings, one fund under the Fuguo Fund has a significant position in Chuanheng Co., Ltd. The Fuguo CSI Value ETF (512040) held 790,100 shares in the third quarter, accounting for 1.38% of the fund's net value, making it the seventh-largest holding [2] - The Fuguo CSI Value ETF (512040) was established on November 7, 2018, with a current scale of 1.675 billion CNY. Year-to-date, it has achieved a return of 19.74%, ranking 2824 out of 4216 in its category. Over the past year, it has returned 19.03%, ranking 1938 out of 3937, and since inception, it has returned 162.93% [2]

Group 1 - The fund manager will determine the specific date for subscription based on actual conditions, and the redemption process will start within three months from the effective date of the fund contract [2] - The fund manager will announce the start date for subscription and redemption in accordance with the relevant regulations prior to the opening date [2] - The fund management company emphasizes the principle of honest credit and diligent management of fund assets, but does not guarantee profits or minimum returns [2] Group 2 - The fund contract will officially take effect on November 12, 2025, marking the beginning of the fund manager's management of the fund [1] - Investors can check transaction confirmation through sales institutions or the fund manager's website and customer service [1] - The acceptance of subscription and redemption applications by sales institutions does not guarantee success, and confirmation is subject to the registration agency's results [1]

Core Insights - The public fund issuance market has seen a significant increase in the number of new funds, reaching 1,371 by November 11, marking a three-year high, while the average fundraising scale has decreased to 782 million yuan [1][2][4] - The market is shifting from a reliance on star fund managers and blockbuster products to a more diversified approach characterized by "tool-oriented, segmented, and institutionalized" strategies [1][4] Fund Issuance Trends - The number of new public funds issued this year has surpassed previous years, with 1,371 new funds compared to 1,266 in 2023 and 1,143 in 2024, nearing the 2022 total of 1,424 [2] - The average fundraising scale for new funds has dropped significantly, with a total issuance scale of approximately 9,653 billion yuan, the lowest since 2019 [4][5] Fund Types and Strategies - A notable trend is the rise of initiated funds, with 334 new funds launched in this format, accounting for about 25% of new funds, primarily in the equity category [4] - The issuance strategy has shifted to "broad net" rather than "creating blockbuster funds," with companies focusing on low-cost, efficient tool products to meet changing market demands [4][5] Market Dynamics - The stock market's recovery has led to a stronger focus on equity funds, with 761 new equity funds issued, a record high, and accounting for 37% of total new fund issuance [6][7] - Conversely, bond funds have seen a significant decline, with only 247 new bond funds issued, the lowest in nearly a decade, reflecting a stark contrast to the equity market's performance [8][9] Future Outlook - The market is expected to maintain a structure where equity funds dominate, particularly index funds due to their cost advantages, while bond fund issuance is anticipated to remain stable [10]

Core Viewpoint - The Hong Kong Stock Connect Dividend ETF managed by Fuguo has shown a positive performance with a recent increase in value and a notable return since its inception [1] Group 1: Fund Performance - The Hong Kong Stock Connect Dividend ETF Fuguo (159277) increased by 0.97% on November 10, with a trading volume of 14.89 million yuan [1] - The fund's latest net asset value is calculated at 134 million yuan, with a total share count of 129 million, reflecting a decrease of 1 million shares on the same day [1] - Over the past 20 trading days, the fund has seen a reduction of 59 million shares [1] Group 2: Returns - Since its establishment on August 5, 2025, the fund has achieved a return of 3.99% [1] - In the last month, the fund's return has been 9.36% [1] Group 3: Management and Benchmark - The fund is managed by Fuguo Fund Management Co., Ltd., with Tian Ximeng as the fund manager [1] - The performance benchmark for the fund is the China Securities Hong Kong Stock Connect High Dividend Investment Index return rate, adjusted using the valuation exchange rate [1]

Group 1 - The core point of the news is that Xi'an Catering Co., Ltd. experienced a stock price increase of 5.15%, reaching 9.40 CNY per share, with a trading volume of 289 million CNY and a turnover rate of 6.17%, resulting in a total market capitalization of 5.395 billion CNY [1] - Xi'an Catering was established on December 31, 1996, and listed on April 30, 1997. The company operates in various sectors including catering, hotels, entertainment, tourism services, construction and renovation, refrigeration equipment, culinary training, technical consulting, and labor technical output [1] - The main revenue composition of Xi'an Catering includes 64.30% from catering services, 23.51% from other income, 5.60% from supplementary sources, 5.00% from merchandise sales, and 1.59% from room revenue [1] Group 2 - The top circulating shareholder of Xi'an Catering is the Fuquan Fund, which increased its holdings in the Fuquan CSI Tourism Theme ETF (159766) by 1.0031 million shares, bringing the total to 2.7994 million shares, representing 0.55% of the circulating shares [2] - The Fuquan CSI Tourism Theme ETF was established on July 15, 2021, with a current scale of 4.927 billion CNY. Year-to-date returns are 6.75%, ranking 3932 out of 4216 in its category, while the one-year return is 0.05%, ranking 3614 out of 3917 [2] - The fund manager of the Fuquan CSI Tourism Theme ETF is Cao Ludi, who has been in the position for 5 years and 176 days, managing a total fund size of 21.209 billion CNY, with the best return during his tenure being 124.03% and the worst being -44.98% [3]

Group 1 - The core point of the news is that Junting Hotel's stock price increased by 5.98%, reaching 22.87 CNY per share, with a total market capitalization of 4.447 billion CNY [1] - Junting Hotel Group, established on August 8, 2007, and listed on September 30, 2021, operates high-end resort and business hotel management, with main revenue sources being accommodation services (67.55%), hotel management (16.21%), dining services (9.76%), and other supporting services (6.47%) [1] Group 2 - Among the top ten circulating shareholders of Junting Hotel, the Fuqua Fund's ETF (159766) increased its holdings by 519,000 shares, totaling 1.5298 million shares, which represents 0.86% of the circulating shares [2] - The Fuqua China Securities Tourism Theme ETF has a current scale of 4.927 billion CNY and has achieved a year-to-date return of 6.75% [2] Group 3 - The fund manager of Fuqua China Securities Tourism Theme ETF is Cao Ludi, who has been in the position for 5 years and 176 days, with the fund's total asset scale at 21.209 billion CNY [3] - During Cao Ludi's tenure, the best fund return was 124.03%, while the worst return was -44.98% [3]

Group 1 - The company, Baillie Gifford, plans to globally offer 8.6343 million shares, with 863,500 shares available in Hong Kong and 7.7708 million shares for international sale [1] - The subscription period is set from November 7 to November 12, with a maximum offer price of HKD 389.00 per share, and the entry fee is approximately HKD 39,292.31 for 100 shares [1] - The total expected fundraising amount is HKD 3.18 billion, with a net amount of HKD 3.018 billion, intended for research and development of biological drug candidates outside mainland China, establishing a global supply chain, and general corporate purposes [1] Group 2 - The company has introduced cornerstone investors including Bristol-Myers Squibb, OAP III (HK) Limited, GL China Long Equity Opportunities SPV L.P., Athos Capital Limited, and Franklin Templeton Investments, who will subscribe to approximately 638,900 shares at the offer price [1] - The company is expected to be listed on the main board on November 17, 2025, with joint sponsors including Goldman Sachs (Asia) LLC, J.P. Morgan Securities (Far East) Limited, and CITIC Securities (Hong Kong) Limited [1] Group 3 - The company's main business includes wholesale of biochemical drugs, biological products (excluding preventive biological products), chemical raw materials, antibiotic raw materials, traditional Chinese medicine, chemical drug formulations, and antibiotic formulations [2] - The net profits for the years 2023, 2024, and the first half of 2025 (ending June 30) are projected to be -780 million, 3.708 billion, and -1.118 billion respectively, with year-on-year changes of -176.40%, 575.02%, and -123.96% [2]

Group 1 - In the first ten months of the year, 943 out of 974 comparable ordinary equity funds achieved positive performance, representing a 97% success rate, with only 31 funds declining [1][3] - The top-performing funds include E Fund Strategic Emerging Industries Stock A and C, with returns of 101.22% and 100.53% respectively, benefiting from the surge in sectors like semiconductors and computing [1][2] - The E Fund Information Industry Selected Stock A and C, managed by veteran Zheng Xi, also performed well, with increases of 98.31% and 97.45%, focusing on semiconductor stocks [2][3] Group 2 - The healthcare-themed funds, such as Huaan Pharmaceutical Biotechnology Stock A and C, saw significant gains of 85.88% and 85.21%, respectively, indicating strong performance in the pharmaceutical sector [3][4] - Despite the overall market rise, only 31 ordinary equity funds reported negative returns, with the largest decline being less than 7% for funds heavily invested in traditional sectors like medicine and liquor [3][4] - The Baoying Brand Consumption Stock A and C experienced declines of 4.71% and 5.39%, attributed to a shift in management and a focus on consumer stocks [4][5] Group 3 - The data from Tonghuashun indicates that the performance of various funds is closely tied to their sector focus, with technology and healthcare leading the gains [1][3] - The report highlights the importance of fund management experience, as seen with managers like Zheng Xi and Ouyang Liangqi, who have extensive backgrounds in industry research [2][3] - The overall trend in the A-share market suggests a strong recovery, with a majority of funds benefiting from sector-specific booms, particularly in technology and healthcare [1][3]

募集期间净认购金额2,999,997,484.42元，认购资金在募集期间产生的利息0元，募集份额合计 2,999,997,484.42份。 基金经理范妍曾任兴业证券股份有限公司助理策略分析师，安信证券股份有限公司高级策略分析 师，工银瑞信基金管理有限公司策略分析师，圆信永丰基金管理有限公司基金经理助理、基金经理、权 益总监、副总经理；自2024年5月加入富国基金管理有限公司，自2024年10月起历任资深权益基金经 理；现任富国基金权益投资部权益投资总监兼资深权益基金经理。 | 基金名称 | 富国兴和混合型证券投资基金 | | --- | --- | | 基金简称 | 富国兴和混合 | | 基金主代码 | 025717 | | 基金运作方式 | 契约型开放式 | | 基金合同生效日 | 2025年11月5日 | | 基金管理人名称 | 富国基金管理有限公司 | | 基金托管人名称 | 兴业银行股份有限公司 | | 公告依据 | 《中华人民共和国证券投资基金法》及配套 法规、《富国兴和混合型证券投资基金基金 合同》、《富国兴和混合型证券投资基金招 | | | 摹说明书》 | | 下属分级基金的基金简称 | 富国兴 ...